Jennifer Altomonte

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.

Oncolytic virotherapy with chimeric rVSV-NDV causes tumor-specific immunity in a DC-activation-dependent manner.

Journal: Molecular therapy. Oncology

Published: July 28, 2026

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Vesicular stomatitis virus (VSV) as an oncolytic therapeutic agent for cancer.

Journal: Advances in cancer research

Published: June 05, 2026

Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.

Development of CAR NK Cell Lines Selectively Targeting Cancer Cells Expressing Membrane Hsp70.

Journal: MedComm

Published: June 30, 2025

Syncytial death mediated by oncolytic rVSV-NDV dynamically activates immunogenic apoptosis and necroptosis in human lung cancer cells.

Syncytial death mediated by oncolytic rVSV-NDV dynamically activates immunogenic apoptosis and necroptosis in human lung cancer cells.

Journal: Molecular therapy. Oncology

Published: March 11, 2025

High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.

High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.

Journal: Engineering in life sciences

Published: February 13, 2025

Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma.

Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma.

Journal: Cancers

Published: December 19, 2024

A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.

A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model.

Journal: Cancers

Published: September 10, 2024

Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.

Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells.

Journal: Blood

Published: June 13, 2024

Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.

Production of recombinant vesicular stomatitis virus-based vectors by tangential flow depth filtration.

Journal: Applied microbiology and biotechnology

Published: October 17, 2023

Characterization of a quail suspension cell line for production of a fusogenic oncolytic virus.

Characterization of a quail suspension cell line for production of a fusogenic oncolytic virus.

Journal: Biotechnology and bioengineering

Published: April 24, 2023

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.

Journal: Molecular therapy oncolytics

Published: February 03, 2023

Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.

Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.

Journal: Biotechnology and bioengineering

Published: November 22, 2022

Showing 1-12 of 31

Last Updated: 09/26/2026